




giuseppe viscardi
695 posts

@giusvisc
MD, PhD. Lung Medical Oncologist at Monaldi Hospital in Naples. AIOM Giovani WG. Fighting against the emperor of all maladies.








MDT Bridge from the other side of the coin: 15% of patients and 30% of borderline resectable will never receive surgery. Maintanance post chemo-RT in a 'PACIFIC style' could be not enough considering the previous exposure to ICI in the neoadjuvant setting @AndrearicFili #ESMO25

2 messages in my opinion from Alex (OS no stat sign with 47% of pts in crizo receiving ALK TKI at PD, and no data stratified for that) & Flaura2 (crossing of curves in NON-high risk pts): - sequencing is possible (better with brain active TKIs) - descalate is possible in low-risk











After hard work, I’m proud to share our newly published Cochrane meta-analysis! 🔍 Adjuvant EGFR-TKIs for resected stage I–III EGFR-mutant NSCLC: what does the evidence really say? cochranelibrary.com/cdsr/doi/10.10… @cochranecollab @MImbimbo1 @RobertoFerrara_ @vittoriosimeon @giusvisc





Ho scritto un libro. Uscirà il prossimo 4 di febbraio, che è anche la giornata mondiale contro il cancro. amzn.eu/d/7OOubJG Cos’è il cancro, perché ci si ammala, cosa succede dopo una diagnosi. Come lo studiamo e trattiamo. E come lo cureremo. Un thread.








Tina Cascone and William N. William provide great commentary in Nature Reviews Clinical Oncology. From our small and sometimes devastated country, we must thank them most sincerely for their comments and recognition. We feel grateful for it. doi.org/10.1038/s41571…






Excited to share our new perspective in #ESMORWD, "Oncology Education in the Age of Artificial Intelligence. we advocate that AI literacy has become a relevant skill x oncologists sciencedirect.com/science/articl… thanks to the co-authors @gfscoazec @Dykex6 and my friend @jnkath @myESMO